Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL589128 | 1.00 | LY96 (0.36) | LY96NFKB1NFKB2RELACYP2C9 | |
| SCHEMBL589127 | 1.00 | LY96 (0.36) | LY96NFKB1NFKB2RELACYP2C9 | |
| SCHEMBL22955561 | 0.91 | CYP2C9 (0.36) | LY96NFKB1NFKB2RELACYP2C9 | |
| SCHEMBL588351 | 0.84 | NFKB1 (0.41) | NFKB1NFKB2RELAFPR2ALDH1A1 | |
| SCHEMBL22955985 | 0.84 | NFKB1 (0.41) | NFKB1NFKB2RELAFPR2ALDH1A1 | |
| SCHEMBL588350 | 0.84 | NFKB1 (0.41) | NFKB1NFKB2RELAFPR2ALDH1A1 | |
| SCHEMBL588353 | 0.84 | NFKB1 (0.41) | NFKB1NFKB2RELAFPR2ALDH1A1 | |
| SCHEMBL588352 | 0.84 | NFKB1 (0.41) | NFKB1NFKB2RELAFPR2ALDH1A1 | |
| SCHEMBL29564631 | 0.84 | NFKB1 (0.41) | NFKB1NFKB2RELAFPR2ALDH1A1 | |
| SCHEMBL18532132 | 0.83 | NFKB1 (0.39) | NFKB1NFKB2RELAFPR2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10322102-B2 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2019-06-18 | — | — | US | disclosed |
| US-20170172967-A1 | Benzo Lipoxin Analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2017-06-22 | — | — | US | disclosed |
| US-9573880-B2 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150073047-A1 | Benzo Lipoxin Analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2015-03-12 | — | — | US | disclosed |
| US-8802881-B2 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120142772-A1 | Benzo Lipoxin Analogues | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-06-07 | — | — | US | disclosed |
| US-8115023-B2 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100152290-A1 | Benzo Lipoxin Analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-06-17 | — | — | US | disclosed |
| US-7683193-B2 | Inflammation, autoimmune disease and abnormal cell proliferation; analogs of 15-epi-lipoxin A4; e.g. (5S,6R,E)-methyl 5,6-dihydroxy-8-(2-(1-hydroxyhexyl)phenyl)oct-7-enoate | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-03-23 | — | — | US | disclosed |
| US-20060270734-A1 | Benzo lipoxin analogues | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-11-30 | — | — | US | disclosed |
| US-20050203184-A1 | Benzo lipoxin analogues | PETASIS NICOS A (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150073047-A1 | Benzo Lipoxin Analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
| US-20050203184-A1 | Benzo lipoxin analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
| US-20170172967-A1 | Benzo Lipoxin Analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
| US-20120142772-A1 | Benzo Lipoxin Analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
| US-20100152290-A1 | Benzo Lipoxin Analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
| US-10322102-B2 | Benzo lipoxin analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
| US-20060270734-A1 | Benzo lipoxin analogues | ALOX15B, ALOX12, ALOX15 | LY96 246/4885NFKB1 175/4885NFKB2 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.